NICE backs restricted use of Ondexxya
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
Read More
Tag: andexanet alfa
NICE rejects NHS funding for Portola’s Ondexxya
NICE says there is “no direct evidence” that the drug is better than existing treatment
Read More
EU to review Portola’s blood-thinner antidote
The group is seeking conditional approval for the drug’s use when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery.
Read More
Portola’s blood thinner antidote turned away by FDA
Portola has been dealt a blow after its anticoagulation reversal drug AndexXa was rejected by the US Food and Drug Administration.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
